Siglec 1 and 2 as potential biomarkers in autoimmune disease

Amanda Eakin, Michael Bustard, Cathy McGeough, Tahanver Ahmed, AJ Bjourson, David Gibson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Autoimmune diseases (AD) are currently treated with anti-inflammatory and immunosuppressive drugs, aimed at reducing symptoms of disease in order to improve quality of life for patients. However, for a significant number of patients these therapies are ineffective, leading to an increased risk of irreversible damage and eventual disability in certain cases. Growing evidence has implicated glycosylated proteins and their cognate receptors in modulation of the autoimmune response. This review will summarise these findings with particular focus on Siglec-1 and -2 involvement in AD. Fluctuations in these glycosylation dependent pathways could act as sentinels of disease activity or drug responses. If validated, protein modification and cellular response markers could help clinicians achieve remission earlier.
LanguageEnglish
JournalProteomics - Clinical Applications
VolumeTBC
Early online date11 Jan 2016
DOIs
Publication statusPublished - 1 Jun 2016

Fingerprint

Sialic Acid Binding Ig-like Lectin 2
Sialic Acid Binding Ig-like Lectin 1
Autoimmune Diseases
Biomarkers
Immunosuppressive Agents
Autoimmunity
Glycosylation
Pharmaceutical Preparations
Proteins
Anti-Inflammatory Agents
Quality of Life
Therapeutics

Keywords

  • Glycosylation
  • Immune tolerance
  • Siglec

Cite this

Eakin, Amanda ; Bustard, Michael ; McGeough, Cathy ; Ahmed, Tahanver ; Bjourson, AJ ; Gibson, David. / Siglec 1 and 2 as potential biomarkers in autoimmune disease. In: Proteomics - Clinical Applications. 2016 ; Vol. TBC.
@article{01611a7e76cd41149bc4bcd9b4e7881e,
title = "Siglec 1 and 2 as potential biomarkers in autoimmune disease",
abstract = "Autoimmune diseases (AD) are currently treated with anti-inflammatory and immunosuppressive drugs, aimed at reducing symptoms of disease in order to improve quality of life for patients. However, for a significant number of patients these therapies are ineffective, leading to an increased risk of irreversible damage and eventual disability in certain cases. Growing evidence has implicated glycosylated proteins and their cognate receptors in modulation of the autoimmune response. This review will summarise these findings with particular focus on Siglec-1 and -2 involvement in AD. Fluctuations in these glycosylation dependent pathways could act as sentinels of disease activity or drug responses. If validated, protein modification and cellular response markers could help clinicians achieve remission earlier.",
keywords = "Glycosylation, Immune tolerance, Siglec",
author = "Amanda Eakin and Michael Bustard and Cathy McGeough and Tahanver Ahmed and AJ Bjourson and David Gibson",
year = "2016",
month = "6",
day = "1",
doi = "10.1002/prca.201500069",
language = "English",
volume = "TBC",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",

}

Siglec 1 and 2 as potential biomarkers in autoimmune disease. / Eakin, Amanda; Bustard, Michael; McGeough, Cathy; Ahmed, Tahanver; Bjourson, AJ; Gibson, David.

In: Proteomics - Clinical Applications, Vol. TBC, 01.06.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Siglec 1 and 2 as potential biomarkers in autoimmune disease

AU - Eakin, Amanda

AU - Bustard, Michael

AU - McGeough, Cathy

AU - Ahmed, Tahanver

AU - Bjourson, AJ

AU - Gibson, David

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Autoimmune diseases (AD) are currently treated with anti-inflammatory and immunosuppressive drugs, aimed at reducing symptoms of disease in order to improve quality of life for patients. However, for a significant number of patients these therapies are ineffective, leading to an increased risk of irreversible damage and eventual disability in certain cases. Growing evidence has implicated glycosylated proteins and their cognate receptors in modulation of the autoimmune response. This review will summarise these findings with particular focus on Siglec-1 and -2 involvement in AD. Fluctuations in these glycosylation dependent pathways could act as sentinels of disease activity or drug responses. If validated, protein modification and cellular response markers could help clinicians achieve remission earlier.

AB - Autoimmune diseases (AD) are currently treated with anti-inflammatory and immunosuppressive drugs, aimed at reducing symptoms of disease in order to improve quality of life for patients. However, for a significant number of patients these therapies are ineffective, leading to an increased risk of irreversible damage and eventual disability in certain cases. Growing evidence has implicated glycosylated proteins and their cognate receptors in modulation of the autoimmune response. This review will summarise these findings with particular focus on Siglec-1 and -2 involvement in AD. Fluctuations in these glycosylation dependent pathways could act as sentinels of disease activity or drug responses. If validated, protein modification and cellular response markers could help clinicians achieve remission earlier.

KW - Glycosylation

KW - Immune tolerance

KW - Siglec

U2 - 10.1002/prca.201500069

DO - 10.1002/prca.201500069

M3 - Article

VL - TBC

JO - Proteomics - Clinical Applications

T2 - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

ER -